From MDS to AML and Back Again:
How Disease Biology Allows Us to
Personalize Therapy

The Webcast Series From MDS to AML and Back Again: How Disease Biology Allows Us to Personalize Therapy was filmed live during a satellite symposium at the 51st American Society of Hematology Annual Meeting. The goal of this series is to improve patient outcomes by educating hematology practitioners and researchers on the distribution and subtypes of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). In addition to pathobiology and clonal evolution, it will also explore disease progression and treatment approaches for patients with MDS or AML syndromes with a focus on overlapping therapies. Presentations will encompass development of treatment strategies that target mechanisms of neoplastic evolution and other basic MDS and AML disorder mechanisms.

	The Changing Clinical Picture of MDS and AML Worldwide
	Estimated Time: 15 minutes Release Date: February 1, 2010 Type: Webcast	Technical Requirements: Windows Media Player Expiration Date: February 1, 2011 Specialties: Hematology / Oncology
	Therapeutic Implications of Molecular Lesions in MDS
	Estimated Time: 30 minutes Release Date: February 23, 2010 Type: Webcast	Technical Requirements: Windows Media Player Expiration Date: February 23, 2011 Specialties: Hematology / Oncology
	Effective Management Strategies for Improving Outcomes in MDS or AML Patients
	Estimated Time: 30 minutes Release Date: February 23, 2010 Type: Webcast	Technical Requirements: Windows Media Player Expiration Date: February 23, 2011 Specialties: Hematology / Oncology
	Clinical Implications: Applying MDS Therapies to AML Patients and Vice-Versa
	Estimated Time: 30 minutes Release Date: February 23, 2010 Type: Webcast	Technical Requirements: Windows Media Player Expiration Date: February 23, 2011 Specialties: Hematology / Oncology
	Patient Involvement in Personalizing Therapy
	Estimated Time: 15 minutes Release Date: February 23, 2010 Type: Webcast	Technical Requirements: Windows Media Player Expiration Date: February 23, 2011 Specialties: Hematology / Oncology
	MDS and AML Therapeutic Strategies: Similarities, Differences, and Overlap
	Estimated Time: 30 minutes Release Date: February 23, 2010 Type: Webcast	Technical Requirements: Windows Media Player Expiration Date: February 23, 2011 Specialties: Hematology / Oncology

Series Objectives

After completing this learning activity, the participant will be able to do the following:

1. Summarize the underlying pathogenesis of MDS and AML and assess its impact on clinical practice.
2. Describe the mechanisms of transformation of MDS to AML.
3. Compare and contrast the treatment goals for MDS and AML and how they overlap.
4. Evaluate the clinical implications of using MDS therapies in AML patients and vice-versa.
5. Design a management strategy plan for improving outcomes in patients with MDS or AML.

Target Audience

This webcast is designed for an international audience of practitioners that includes medical oncologists, hematologists, clinical and translational researchers, and other physicians and allied health care professionals treating patients with MDS or AML. In addition, members of patient advocacy groups will benefit from this program.

Activity Directors

Mikkael A. Sekeres, MD, MS
Associate Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Accreditation

These activities have been approved for AMA PRA Category 1 Credit™.